Cynapsus Therapeutics (CYNA) Down on FDA Fast-Track

Cynapsus Therapeutics Inc. CYNA shares docked 0.7% to $18.39, after the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for APL-130277, a product candidate for the treatment of OFF episodes in patients with Parkinson's disease. Share volume was 21,000, compared to an all-day average of 64,000
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!